Azathioprine immunosuppression and disease modification in Parkinson’s disease (AZA-PD): a randomised double-blind placebo-controlled phase II clinical trial
Objective: To design a clinical trial to test the concept that the immune system is integral in the progression of Parkinson’s disease (PD) and establish…Cinpanemab in Early Parkinson’s Disease: Phase 2 SPARK Study Results
Objective: To evaluate cinpanemab (BIIB054) efficacy and safety. Background: Aggregated alpha-synuclein (α-syn), a major constituent of Lewy bodies, is thought to play a central role…Decreased expression of trace amines receptors on lymphocytes in Parkinson’s disease
Objective: To determine the expression of TAAR1 and TAAR2 mRNA in leukocytes of patients with Parkinson's disease, depending on the stage of the disease and…RESPONDING TO COVID-19: THE “ALMEIDA-SANG EQUATION” TO PREDICT TOTAL DISEASE SEVERITY IN PARKINSON’S
Objective: To predict total disease severity in Parkinson’s disease (PD) for online assessments. Background: Assessment (and hence management) of PD has largely been affected by…Quantitative systems pharmacology modelling of Parkinson’s disease to compare anti-α-synuclein therapeutics
Objective: We previously constructed a quantitative systems pharmacology (QSP) model of Parkinson’s disease (PD) that combines pathogenesis and spatial propagation of misfolded α-synuclein (Asyn) [1].…Determination of the motor status after the implementation Levodopa-carbidopa intestinal gel in patients with advanced Parkinson’s disease using a Machine learning Algorithm
Objective: Aim of this study was to develop a random forest (RF)-based PD model to determine the postoperative motor outcome at 2 years follow-up after…Directional steering in subthalamic deep brain stimulation for Parkinson’s disease: the Berlin experience
Objective: To review the use of directional current steering in a Berlin cohort implanted with segmented leads between 2016-2019. Background: The dorsolateral area of the subthalamic…Effects of Once-Daily Opicapone 50 mg on the Pharmacokinetics of Levodopa Administered as Carbidopa/Levodopa Extended-Release Capsules: An Open-Label Phase 1 Study
Objective: To assess the effects of opicapone 50 mg on the pharmacokinetics (PK) of levodopa (LD) and its metabolite, 3-O-methyldopa (3-OMD), when administered with oral…Levodopa/carbidopa intestinal gel (LCIG) reduces fluctuations and shortens time to on without troublesome dyskinesia in advanced Parkinson’s Disease: Post-hoc analyses of 54-week LCIG-monotherapy trial
Objective: To assess the long-term effectiveness of LCIG monotherapy on reducing daily health-state fluctuations and time to on without troublesome dyskinesia (ONwoTD) after waking Background:…Limitations of conventional dopaminergic medication in advanced Parkinson’s disease: results from 127 patients treated with Levodopa Carbidopa Intestinal Gel
Objective: To evaluate the characteristics of the last conventional dopaminergic treatments in a large cohort of patients with advanced Parkinson’s Disease (APD) treated with Levodopa…
- « Previous Page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- …
- 132
- Next Page »